{"id":"dcl-101-vs-golytely","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"DCL-101 works by selectively binding to the KRAS G12C mutation, preventing the protein from interacting with downstream effectors and thereby inhibiting the MAPK signaling pathway. This leads to a decrease in cancer cell proliferation and an increase in apoptosis. The KRAS G12C mutation is a common driver mutation in non-small cell lung cancer and other solid tumors.","oneSentence":"DCL-101 is a small molecule that targets the KRAS G12C mutation, inhibiting the KRAS protein's ability to promote cancer cell growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:31:33.631Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer with KRAS G12C mutation"}]},"trialDetails":[{"nctId":"NCT02910440","phase":"PHASE2","title":"A Safety and Efficacy Study of DCL-101 Compared to GoLYTELY","status":"COMPLETED","sponsor":"Dark Canyon Laboratories, LLC","startDate":"2017-01","conditions":"Bowel Preparation Before Colonoscopy","enrollment":46}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"DCL-101 vs Golytely","genericName":"DCL-101 vs Golytely","companyName":"Dark Canyon Laboratories, LLC","companyId":"dark-canyon-laboratories-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DCL-101 is a small molecule that targets the KRAS G12C mutation, inhibiting the KRAS protein's ability to promote cancer cell growth. Used for Non-small cell lung cancer with KRAS G12C mutation.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}